中性粒细胞衍生的蛋白酶在肺炎:老玩家和新的前景
Coby J Cheetham1, Michael C McKelvey1, Daniel F McAuley2
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine and Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast BT9 7BL, UK.
International journal of molecular sciences
|May 25, 2024
概括
中性粒细胞蛋白酶驱动肺炎. 虽然中性粒细胞血清蛋白酶 (NSP) 在临床上取得了有限的成功,但像甲素这样的新型蛋白酶为炎症性肺部疾病提供了新的治疗点.
科学领域:
- 肺部医学 肺部医学
- 生物化学 生物化学
- 炎症研究 炎症研究
背景情况:
- 中性粒细胞衍生蛋白酶是急性和慢性炎症性肺病的关键参与者.
- 中性粒细胞血清蛋白酶 (NSP) 已被广泛研究,但临床抑制试验产生了不同的结果.
- 研究正在扩展到参与中性粒细胞功能的研究较少的蛋白酶.
研究的目的:
- 审查NSP在肺炎中的作用,并讨论临床试验的限制.
- 探索其他中性粒细胞蛋白酶的新兴研究.
- 突出新型蛋白酶点治疗中性粒细胞介导的肺炎.
主要方法:
- 对中性粒细胞蛋白酶研究的文献综述.
- 对NSP抑制剂临床试验结果的分析.
- 讨论关于cathepsins,metzincins和calpains的新兴研究.
主要成果:
- NSPs对肺组织损伤和炎症有显著的贡献.
- 临床抑制NSP在肺部疾病患者中已显示出可变的疗效.
- 其他蛋白酶家族 (cathepsins,metzincins,calpains) 越来越多地被认为是它们的角色.
结论:
- 仅仅针对NSP可能不足以治疗炎症性肺部疾病.
- 模糊的中性粒细胞蛋白酶代表了有希望的新治疗点.
- 开发这些新型蛋白酶的抑制剂可能会导致中性粒细胞介导的肺炎的有效治疗方法.
相关概念视频
Inflammation
53.4K
Overview
53.4K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Role of Matrix Metalloproteases in Degradation of ECM
2.4K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.4K


